# reload+after+2024-01-20 18:43:23.967805
address1§251 Consumers Road
address2§Suite 1105
city§Toronto
state§ON
zip§M2J 4R3
country§Canada
phone§647 479 9828
website§https://www.aptose.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin's lymphomas, as well as AML and HR MDS. It has agreements with CrystalGenomics, Inc. and Hanmi Pharmaceutical Co. Ltd. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada.
fullTimeEmployees§35
companyOfficers§[{'maxAge': 1, 'name': 'Dr. William G. Rice Ph.D.', 'age': 64, 'title': 'Chairman, President, CEO & Chief Accounting Officer', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 920799, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Fletcher  Payne', 'age': 60, 'title': 'Senior VP, CFO, Chief Business Officer & Secretary', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 571087, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rafael  Bejar M.D., Ph.D.', 'age': 51, 'title': 'Senior VP & Chief Medical Officer', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 668381, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Philippe  Ledru', 'age': 56, 'title': 'Senior VP & Chief Commercial Officer', 'yearBorn': 1967, 'fiscalYear': 2022, 'totalPay': 644242, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Roger  Davies B.Sc.', 'title': 'Vice President of Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Marc  Wiles Ph.D.', 'title': 'Senior Vice President of Regulatory Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Brooks  Ensign M.B.A.', 'title': 'VP & Controller', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§8
compensationRisk§9
shareHolderRightsRisk§7
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.356
currency§USD
dateShortInterest§1702598400
forwardEps§-5.46
exchange§NCM
quoteType§EQUITY
shortName§Aptose Biosciences, Inc.
longName§Aptose Biosciences Inc.
firstTradeDateEpochUtc§700756200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§abb612cb-7f65-3d78-b951-26e228236bcd
gmtOffSetMilliseconds§-18000000
targetHighPrice§23.0
targetLowPrice§12.0
targetMeanPrice§15.83
targetMedianPrice§15.0
recommendationMean§1.8
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§1.431
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
